We are live on
!
Find out more
MCM
M28 Capital Management Portfolio holdings
AUM
$53.8M
1-Year Est. Return
28.63%
This Fund
S&P 500
This Quarter
Est. Return
-47.5%
1 Year Est. Return
+28.63%
3 Year Est. Return
+218.52%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$53.8M
AUM Growth
-$83.8M
(-61%)
Cap. Flow
-$20.2M
Cap. Flow
% of AUM
-37.55%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
–
Reduced
7
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
Wave Life Sciences
WVE
|
+$14M |
| 2 |
TG Therapeutics
TGTX
|
+$2.18M |
| 3 |
Arrowhead Research
ARWR
|
+$1.93M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
+$695K |
| 5 |
ProQR Therapeutics
PRQR
|
+$688K |
Sector Composition
| 1 | Healthcare | 100% |
Similar funds
YAVAPFMC
NCM
WEO
MML
CAM
ETCM
AA
TP
M28 Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, M28 Capital Management held 9 positions worth $53.8M, down 61% from $138M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
M28 Capital Management withdrew a net $20.2M in Q1 2026, reducing 7 holdings. Its largest reduction was Wave Life Sciences, cutting an estimated $14M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- M28 Capital Management's biggest Q1 2026 reduction was Wave Life Sciences, cutting an estimated $14M.
- M28 Capital Management's ten largest holdings make up 100% of its $53.8M portfolio in Q1 2026.
- M28 Capital Management opened 0 new positions and closed 0 in Q1 2026.
- M28 Capital Management's portfolio value fell 61% quarter-over-quarter to $53.8M.
Based on M28 Capital Management's 13F filing for Q1 2026, filed 14 May 2026.